This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

8 Stocks Surging on Big Volume

Sarepta Therapeutics

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Sarepta Therapeutics (SRPT - Get Report) is a biopharmaceutical company focused on the discovery and development of RNA-based therapeutics for the treatment of both rare and infectious diseases. This stock is trading up 16% at $12.53 in recent trading.

Today's Volume: 2.4 million

Average Volume: 888,214

Volume % Change: 325%

Shares of SRPT are ripping higher today after ThinkEquity initiated coverage on the stock with a buy rating and a $15 price target.

>>5 Stocks Poised for Breakouts

From a technical perspective, SRPT is exploding higher here with above average volume, and this stock has entered breakout territory since it's moved above some near-term overhead resistance at $10.78.

Traders should now look for long-biased trades as long as SRPT is trending above that breakout level of $10.78 or today's low of $11.65 with strong upside volume flows. I would consider any upside volume day that registers near or above 888,214 shares as bullish. If we continue to see that action, then SRPT has a great chance of hitting $15 in the near future.

Cornerstone OnDemand

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

3 of 9

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ACTG $10.62 0.00%
CSOD $29.49 0.00%
IMGN $8.25 0.00%
SRPT $13.57 0.00%
VNET $16.98 0.00%


DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs